Hemodez-H (Haemodes-N)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8 Thousand.Potassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8thousand
Similar drugsTo uncover
  • Hemodez-8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Hemodez-H
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    MOSFARM, LLC    
  • Hemodez-H
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Hemodez-H
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    Kursk Biofactory - BIOK, FKP     Russia
  • Hemodez-H
    solution d / infusion 
    RESTER, CJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ELFARMI, LTD.     Russia
  • Hemodez-H
    solution d / infusion 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ATOLL, LLC     Russia
  • Krasgemodez 8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Krasgemodez 8000
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Neohemodes
    solution in / in 
    SYNTHESIS, OJSC     Russia
  • Neohemodes
    solution inwards 
    FIRM MEDPOLIMER, JSC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    1 liter of solution contains: polyvinylpyrrolidone low molecular weight medical 8000 ± 2000 (povidone) (in terms of anhydrous) - 60 g; sodium chloride - 5.5 g, potassium chloride - 0.42 g,calcium chloride hexahydrate - 0.5 g, magnesium chloride hexahydrate - 0.005 g, sodium hydrogen carbonate - 0.23 g, water for injection up to 1 liter.

    Description:Transparent liquid from light yellow to yellow.
    Pharmacotherapeutic group:Detoxifying agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    The action of Hemodesa-H is due to the ability of low molecular weight polyvinylpyrrolidone to bind toxins circulating in the blood and rapidly excreted from the body by the kidneys. The drug has diuretic activity due to increased renal blood flow and increased glomerular filtration. Promotes improvement of microcirculation in capillaries and elimination of stasis of erythrocytes, which develops with intoxications of any origin.

    Pharmacokinetics:It is not metabolized in the body. During the first 4 hours 80% of the drug is withdrawn, and through 12-24 hours - completely.
    Indications:

    - Shock: post-traumatic, postoperative, burn, hemorrhagic;

    - Toxic forms of acute infectious diseases of the gastrointestinal tract (including dysentery, salmonellosis);

    - Intoxications of various origins: postoperative, cancerous, radiation, alcoholic, in connection with hepatic and renal insufficiency; Burn disease in the phase of intoxication (2-5 day of illness); acute radiation sickness in the phase of intoxication (1-3 days of illness); hemolytic disease of newborns, intrauterine infection and toxemia of newborns, peritonitis and intestinal obstruction;

    - Edema with toxicosis of pregnant women, thyrotoxicosis, sepsis, chronic liver diseases (hepatitis, hepato-cholangitis, liver dystrophy), acute phase of myocardial infarction.

    Contraindications:

    Hypersensitivity to the drug, intracranial hypertension, hemorrhagic stroke, condition after traumatic brain injury, cardiovascular insufficiency IIb - III degree, respiratory failure, severe allergic reactions, thromboembolism, oliguria, anuria, acute nephritis, bronchial asthma, phlebothrombosis.

    Carefully:Not described.
    Pregnancy and lactation:Not described.
    Dosing and Administration:

    Intravenously drip, through a system with a filter.

    The dose of the drug, depending on the age of the patient and the intensity of intoxication is different.

    For adults, the single maximum dose is 400 ml. The therapeutic effect is manifested at a dose of 1.5 ml / kg

    Patients with large focal myocardial infarction on day 1 of Hemodesis-H disease are given a dose of 200 ml. In some cases (prolonged pain, severe arrhythmias, cardiogenic shock, or a combination of these complications with concomitant diabetes), the drug is given again on the 2nd day in the same dose (200 ml).

    For infants - 5-10 ml / kg. The maximum single dose for them is 70 ml; for children from 2 to 5 years - 100 ml; from 5 to 10 years - 150 ml; from 10 to 15 years - 200 ml.

    Side effects:

    Allergic reactions of varying severity (up to the development of anaphylactic shock). Introduction with increased speed can cause lowering of blood pressure, tachycardia, difficulty breathing.

    If the introduction of the drug develops the initial signs of an adverse reaction, it is necessary to stop the infusion of the drug, to carry out symptomatic treatment.

    Overdose:Not described.
    Interaction:Not described.
    Special instructions:

    During the treatment it is necessary to monitor the level of blood pressure and carefully monitor the patient's condition.

    Effect on the ability to drive transp. cf. and fur:Not described.
    Form release / dosage:Solution for infusion.
    Packaging:By 250 ml or 500 ml into polymeric containers of multilayer film based on polypropylene. The container is placed in a bag of polyethylene film together with instructions for use or the text of the instruction is applied directly to the package. Containers in plastic bags are placed in boxes of corrugated cardboard. Containers without secondary packaging with instructions for use are placed in boxes of cardboard corrugated (for hospitals).
    Storage conditions:

    In a dry place at a temperature of 5 ° C to 25 ° C FROM. Keep out of the reach of children. Freezing the drug (provided the seal is tight) and non-wetting of the inner surface is not a contraindication to its use.

    Shelf life:2 years. Do not use after expiry date.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-001893
    Date of registration:11.08.2006
    Expiration Date:11.08.2011
    The owner of the registration certificate:PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.03.2017
    Illustrated instructions
      Instructions
      Up